Generic Altoprev Availability
ALTOPREV (lovastatin - tablet, extended release;oral)
Manufacturer: COVIS PHARMA SARL
Approval date: June 26, 2002
Strength(s): 20MG, 40MG, 60MG [RLD]
Has a generic version of Altoprev been approved?
No. There is currently no therapeutically equivalent version of Altoprev available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Altoprev. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
HMG co-reductase inhibitor
Issued: June 29, 1999
Inventor(s): Chen; Chih-Ming & Chou; Joseph & Wong; David
Assignee(s): Andrx Pharmaceutials, Inc.
A controlled release dosage formulation is described which is based on a combination of: (a) a compressed tablet core which contains an alkyl ester of a hydroxy substituted naphthalene derivative a pharmaceutically acceptable, water swellable polymer and an osmotic agent; and (b) an outer coating layer which completely covers the osmotic core and comprises a pH sensitive coating agent and a water insoluble polymer.Patent expiration dates:
- December 12, 2017
- December 12, 2017
Methods for decreasing beta amyloid protein
Issued: June 27, 2000
Inventor(s): Yankner; Bruce A. & Nadeau; Philip
Assignee(s): Children's Medical Center Corporation
Blood cholesterol levels are correlated with production of amyloid .beta. protein (A.beta.), and are predictors of populations at risk of developing AD. Methods for lowering blood cholesterol levels can be used to decrease production of A.beta., thereby decreasing the risk of developing AD. The same methods and compositions can also be used for treating individuals diagnosed with AD. Methods include administration of compounds which increase uptake of cholesterol by the liver, such as the administration of HMG CoA reductase inhibitors, administration of compounds which block endogenous cholesterol production, such as administration of HMG CoA reductase inhibitors, administration of compositions which prevent uptake of dietary cholesterol, and administration of combinations of any of these which are effective to lower blood cholesterol levels. Methods have also been developed to predict populations at risk, based on the role of cholesterol in production of A.beta.. For example, individuals with Apo E4 and high cholesterol, defined as a blood cholesterol level of greater than 200 mg/dl, post menopausal women with high cholesterol levels--especially those who are not taking estrogen, or individuals which high blood cholesterol levels who are not obese are all at risk of developing AD if blood cholesterol levels are not decreased.Patent expiration dates:
- March 23, 2018✓
- March 23, 2018
Once daily pharmaceutical tablet having a unitary core
Issued: November 26, 2002
Inventor(s): Chih-Ming; Chen & Joseph C. H.; Chou
Assignee(s): Andrx Pharmaceuticals, Inc.
A controlled release tablet is disclosed which comprises: (a) a homogeneous compressed core which comprises: (i) a medicament which is very slightly soluble to practically insoluble in water at 25° C.; (ii) a water soluble osmotic compound (iii) one or more osmotic polymers; and (b) a membrane coating which completely covers said core tablet which comprises a mixture of a: (i) a water insoluble pharmaceutically acceptable polymer; and (ii) a pH dependent polymer such as an enteric coating polymer, the weight ratio of the pH dependent polymer to the water insoluble pharmaceutically acceptable polymer being 0.1:1 to 0.75:1. A controlled release tablet which comprises: (a) a medicament (a) a homogeneous compressed core which comprises: (i) a medicament; (ii) a water soluble osmotic compound (iii) one or more osmotic polymers; and (b) a membrane coating which completely covers said core tablet which comprises a mixture of: (i) a water insoluble pharmaceutically acceptable polymer; and (ii) an enteric polymer.Patent expiration dates:
- December 12, 2017✓
- December 12, 2017
More about Altoprev (lovastatin)
Related treatment guides
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|